A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
A legfontosabb adatok
- Hol
- Bay City, Bexley, Birmingham, Boston, Bridgeport, Chapel Hill, Charlotte, Chesterfield, Cleveland, Coral Gables, East Greenwich, Fort Gratiot, Fremont, Houston, Indianapolis, Mason, Miami, New Brighton, Norfolk, Northridge, Owensboro, Portland, Raleigh, Rockville, Saint Joseph, San Antonio, San Francisco, Scottsdale, South Bend, Tampa, Troy és Tulsa (Egyesült Államok)Mind a 33 helyszín megnézése
- Fázis
- 3. fázis
Helyszínek itt: Egyesült Államok
- Great Lakes Research Group, Inc.Bay City, Egyesült ÁllamokNo longer taking part
- Bexley Dermatology ResearchBexley, Egyesült ÁllamokNo longer taking part
- Total Skin and Beauty Dermatology Center, PCBirmingham, Egyesült ÁllamokNo longer taking part
- Tufts Medical CenterBoston, Egyesült ÁllamokNo longer taking part
- New England Research AssociatesBridgeport, Egyesült ÁllamokNo longer taking part
- The University of North Carolina at Chapel HillChapel Hill, Egyesült ÁllamokNo longer taking part
- Dermatology Specialists of CharlotteCharlotte, Egyesült ÁllamokNo longer taking part
- Clinical Research Institute of Michigan, LLCChesterfield, Egyesült ÁllamokNo longer taking part
- University Hospitals Cleveland Medical Center*Cleveland, Egyesült ÁllamokNo longer taking part
- Florida Academic Centers Research and Education, LLCCoral Gables, Egyesült ÁllamokNo longer taking part
- Velocity Clinical Research, ProvidenceEast Greenwich, Egyesült ÁllamokNo longer taking part
- Hamzavi DermatologyFort Gratiot, Egyesült ÁllamokNo longer taking part
- Center For Dermatology Clinical Research, Inc.Fremont, Egyesült ÁllamokNo longer taking part
- Suzanne Bruce and Associates, PAHouston, Egyesült ÁllamokNo longer taking part
- Dawes Fretzin Clinical Research Group, LLCIndianapolis, Egyesült ÁllamokNo longer taking part
- Dermatologists of Southwest OhioMason, Egyesült ÁllamokNo longer taking part
- New Horizon Research CenterMiami, Egyesült ÁllamokNo longer taking part
- Associated Skin Care SpecialistsNew Brighton, Egyesült ÁllamokNo longer taking part
- Virginia Clinical Research, Inc.Norfolk, Egyesült ÁllamokNo longer taking part
- Quest Dermatology ResearchNorthridge, Egyesült ÁllamokNo longer taking part
- Qualmedica Research, LLCOwensboro, Egyesült ÁllamokNo longer taking part
- Northwest Dermatology InstitutePortland, Egyesült ÁllamokNo longer taking part
- Oregon Dermatology and Research CenterPortland, Egyesült ÁllamokNo longer taking part
- M3-Emerging Medical ResearchRaleigh, Egyesült ÁllamokNo longer taking part
- Dermatology and Skin Cancer SpecialistsRockville, Egyesült ÁllamokNo longer taking part
- Medisearch Clinical TrialsSaint Joseph, Egyesült ÁllamokNo longer taking part
- Progressive Clinical ResearchSan Antonio, Egyesült ÁllamokNo longer taking part
- Kaiser Permanente HospitalSan Francisco, Egyesült ÁllamokNo longer taking part
- Investigate MdScottsdale, Egyesült ÁllamokNo longer taking part
- The South Bend Clinic Center for ResearchSouth Bend, Egyesült ÁllamokNo longer taking part
- ForCare Clinical ResearchTampa, Egyesült ÁllamokNo longer taking part
- Joseph J. Schwartz, M.D.Troy, Egyesült ÁllamokNo longer taking part
- Vital Prospects Clinical Research Institute, P.C.Tulsa, Egyesült ÁllamokNo longer taking part
A vizsgálat adatai
- Ki végzi
- Eli Lilly and Company
- Azonosító
- NCT03899259
- A regiszteradat frissítve
- 2026. április 7.
- Eredeti leírás
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).A teljes eredeti leírásKevesebb
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Bevonási feltételek: Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent; Have severe or very severe AA, as determined by all of the following:; Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and baseline; No spontaneous improvement over the past 6 months; Current episode of severe or very severe AA of less than 8 years. Note: participants who have severe or very severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years; Male or nonpregnant, nonbreastfeeding female participants.
Kizáró feltételek: Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA; Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment); Primarily "diffuse" type of AA.